Advances in Early Detection and Diagnostic Adjuncts in Oral Cavity Cancer

Farah, Camile S.; Bhatia, Nirav; Lalla, Yastira; Vu, Anthony; John, Keziah; Gupta, Vishal; Baeten, John; Johnson, Alexander D.; Kademani, Deepak

doi:10.1007/978-3-319-14911-0_9

Cited by 8 publications

(6 citation statements)

References 267 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, around half of the lesions were easier to visualize (increased brightness and/or sharpness) compared to COE. 36 This finding was confirmed by several groups who concluded that the ViziLite is not useful as a diagnostic tool but can help increase visibility of lesions (reviewed in study by Farah et al 21 ).…”

Section: Chemiluminescencementioning

confidence: 85%

“…1,2,7,14,15,20 The following screening methods are the most commonly discussed current screening methods ( Figure 1), but others have been introduced as well. 21…”

Section: Current Screening Methodsmentioning

confidence: 99%

“…Glycans are a promising cellular target, as it has been demonstrated that glycosylation is significantly altered in cancer cells when compared to healthy cells. 21,61,62 A tool for imaging these changes is through lectins. Lectins react with the terminal, nonreducing sugars of glycoproteins and glycolipids and, therefore, have been explored for molecularly targeted imaging of malignant cells.…”

Section: Molecularly Targeted Approachesmentioning

confidence: 99%

“…70 Yet, the concept of imaging glucose metabolism is promising for visualizing early malignancy. 21 Therefore, a fluorescent analogue of 18 F-FDG, 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG), was synthesized and has been tested in oral cancer. 70,77 Nitin et al demonstrated when 2-NBDG was topically applied to oral biopsy specimens, based on analysis of wide field imaging, there was a 15- to 40-fold increase in signal in tumor when compared to normal tissue (Figure 5b).…”

Section: Molecularly Targeted Approachesmentioning

confidence: 99%

See 3 more Smart Citations

Current Practice and Emerging Molecular Imaging Technologies in Oral Cancer Screening

et al. 2018

View full text Add to dashboard Cite

Oral cancer is one of the most common cancers globally. Survival rates for patients are directly correlated with stage of diagnosis; despite this knowledge, 60% of individuals are presenting with late-stage disease. Currently, the initial evaluation of a questionable lesion is performed by a conventional visual examination with white light. If a lesion is deemed suspicious, a biopsy is taken for diagnosis. However, not all lesions present suspicious under visual white light examination, and there is limited specificity in differentiating between benign and malignant transformations. Several vital dyes, light-based detection systems, and cytology evaluation methods have been formulated to aid in the visualization process, but their lack of specific biomarkers resulted in high false-positive rates and thus limits their reliability as screening and guidance tools. In this review, we will analyze the current methodologies and demonstrate the need for specific intraoral imaging agents to aid in screening and diagnosis to identify patients earlier. Several novel molecular imaging agents will be presented as, by result of their molecular targeting, they aim to have high specificity for tumor pathways and can support in identifying dysplastic/cancerous lesions and guiding visualization of biopsy sites. Imaging agents that are easy to use, inexpensive, noninvasive, and specific can be utilized to increase the number of patients who are screened and monitored in a variety of different environments, with the ultimate goal of increasing early detection.

show abstract

Section: Chemiluminescencementioning

confidence: 85%

“…1,2,7,14,15,20 The following screening methods are the most commonly discussed current screening methods ( Figure 1), but others have been introduced as well. 21…”

Section: Current Screening Methodsmentioning

confidence: 99%

Section: Molecularly Targeted Approachesmentioning

confidence: 99%

Section: Molecularly Targeted Approachesmentioning

confidence: 99%

See 2 more Smart Citations

Current Practice and Emerging Molecular Imaging Technologies in Oral Cancer Screening

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Tumor heterogeneity is contributed by various components including cellular and non-cellular components such as oncometabolite [ 1 , 2 ]. Mutual exchanges of various metabolites are an important feature among cancer cells and non-cancer cells including immune cells, stromal cells, and microbiotas in the niche of the oral tumor microenvironment (3–4).…”

Section: Introductionmentioning

confidence: 99%

Detection of Nail Oncometabolite SAICAR in Oral Cancer Patients and Its Molecular Interactions with PKM2 Enzyme

Patel

Raj

Lokhande

et al. 2021

IJERPH

View full text Add to dashboard Cite

Oncometabolites are known to drive metabolic adaptations in oral cancer. Several oncometabolites are known to be shared between cancer cells and non-cancer cells including microbiotas to modulate the tumor microenvironment. Among potential oncometabolites, succinylaminoimidazolecarboxamide ribose5′-phosphate (SAICAR) supports the growth and invasiveness of cancer cells by pyruvate kinase M2 (PKM2) enzyme in a glucose starved tumor microenvironment. There is a significant gap that shows the detection of SAICAR in biological samples including nails of oral cancer patients. Metabolite identification of SAICAR was investigated in the nails of oral cancer patients using novel vertical tube gel electrophoresis (VTGE) and LC-HRMS. Further molecular docking and molecular dynamics simulations (MDS) were employed to determine the nature of molecular interactions of SAICAR (CHEBI ID:18319) with PKM2 (PDB ID: 4G1N). Molecular docking of SAICAR (CHEBI ID:18319) was performed against pyruvate kinase M2 (PDB ID: 4G1N). Data suggest the presence of oncometabolite SAICAR in nails of oral cancer. Molecular docking of SAICAR with PKM2 showed appreciable binding affinity (−8.0 kcal/mol) with residues including ASP407, THR405, GLU410, ARG443, GLY321, ARG436, HIS439, LYS266, and TYR466. Furthermore, MDS confirmed the specific binding of SAICAR within the activator site of PKM2 and the stability of SAICAR and PKM2 molecular interactions. In conclusion, SAICAR is a promising oncometabolite biomarker present in the nails of oral cancer patients. A significant activation potential of SAICAR exists with the PKM2 enzyme.

show abstract

Noninvasive Early Biomarkers and Chemopreventive Strategies for Oral Cancer and Oral Potentially Malignant Disorders: New Advancements and Future Perspectives

Polizzi,

Cicciù,

Leonardi

et al. 2024

Interdisciplinary Cancer Research

View full text Add to dashboard Cite

Advances in Early Detection and Diagnostic Adjuncts in Oral Cavity Cancer

Cited by 8 publications

References 267 publications

Current Practice and Emerging Molecular Imaging Technologies in Oral Cancer Screening

Current Practice and Emerging Molecular Imaging Technologies in Oral Cancer Screening

Detection of Nail Oncometabolite SAICAR in Oral Cancer Patients and Its Molecular Interactions with PKM2 Enzyme

Noninvasive Early Biomarkers and Chemopreventive Strategies for Oral Cancer and Oral Potentially Malignant Disorders: New Advancements and Future Perspectives

Contact Info

Product

Resources

About